Dr Reddys is currently trading at Rs. 2403.15, up by 11.75 points or 0.49% from its previous closing of Rs. 2391.40 on the BSE.
The scrip opened at Rs. 2390.00 and has touched a high and low of Rs. 2413.25 and Rs. 2374.00 respectively. So far 9861 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2482.00 on 21-Oct-2013 and a 52 week low of Rs. 1661.75 on 26-Oct-2012.
Last one week high and low of the scrip stood at Rs. 2482.00 and Rs. 2354.55 respectively. The current market cap of the company is Rs. 40,969 crore.
The promoters holding in the company stood at 25.52% while Institutions and Non-Institutions held 41.44% and 16.16% respectively.
Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Generic Navelbine injection. The said injection is anti-cancer chemotherapy drug which used for Non-small cell lung cancer. Moreover, some healthcare providers may also give Navelbine for breast cancer, ovarian cancer, or Hodgkin’s disease.
Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
The scrip opened at Rs. 2390.00 and has touched a high and low of Rs. 2413.25 and Rs. 2374.00 respectively. So far 9861 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2482.00 on 21-Oct-2013 and a 52 week low of Rs. 1661.75 on 26-Oct-2012.
Last one week high and low of the scrip stood at Rs. 2482.00 and Rs. 2354.55 respectively. The current market cap of the company is Rs. 40,969 crore.
The promoters holding in the company stood at 25.52% while Institutions and Non-Institutions held 41.44% and 16.16% respectively.
Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Generic Navelbine injection. The said injection is anti-cancer chemotherapy drug which used for Non-small cell lung cancer. Moreover, some healthcare providers may also give Navelbine for breast cancer, ovarian cancer, or Hodgkin’s disease.
Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
No comments:
Post a Comment